Research programme: recombinant protein factor V - Leiden/Cambridge

Drug Profile

Research programme: recombinant protein factor V - Leiden/Cambridge

Alternative Names: Recombinant protein factor V - Leiden/Cambridge

Latest Information Update: 20 Jun 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Crucell
  • Class Recombinant proteins
  • Mechanism of Action Factor V stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Haemophilia A

Most Recent Events

  • 22 Feb 2011 Crucell has been acquired by Johnson & Johnson
  • 16 Nov 2006 Preclinical trials in Haemophilia A in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top